Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
Leslie Citrome, Christine Graham, Adam Simmons, et al.
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 2885-2904
Open Access | Times Cited: 16

Showing 16 citing articles:

Current Pharmacological Treatments for Bipolar Disorder
Nicole W. Simons, Alexander W. Charney
Oxford University Press eBooks (2025), pp. 317-328
Closed Access
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia
Christie Monahan, Lindsey McCoy, Jason Powell, et al.
Annals of Pharmacotherapy (2022) Vol. 56, Iss. 9, pp. 1049-1057
Closed Access | Times Cited: 17
Schizophrenia Management: Systematic Review of Current Medications and Phase-3 Agents (2008–2024)
Salma Abdelmoteleb, Jayant Totlani, Salma Ramadan, et al.
Neuroscience Applied (2025) Vol. 4, pp. 105507-105507
Open Access
Psychotropic drugs, eating behaviour and weight gain
Shalika Arniotis-Streat, Anthony Fonte, Hisham Ziauddeen
Current Opinion in Psychiatry (2024) Vol. 37, Iss. 5, pp. 331-336
Closed Access | Times Cited: 2
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine
Roger S. McIntyre, Leslie Citrome, Hannah Cummings, et al.
CNS Spectrums (2022) Vol. 28, Iss. 3, pp. 288-299
Open Access | Times Cited: 9
Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials
Syeda Tayyaba Rehan, Abdul Hannan Siddiqui, Zayeema Khan, et al.
Annals of Medicine and Surgery (2022) Vol. 79
Open Access | Times Cited: 9
Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis
Zhenlei Peng, Qiyu Jia, Junxiong Mao, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 2295-2308
Open Access | Times Cited: 4
Pharmacologic Treatment of Schizophrenia Beyond Dopamine Receptor Blockade—Has Its Time Come Yet?
Christoph U. Correll, Leslie Citrome
JAMA Psychiatry (2023) Vol. 81, Iss. 2, pp. 118-118
Closed Access | Times Cited: 4
Overview of approved psychiatric medications 2008-2023: A systematic review
Waguih William IsHak, Jayant Totlani, Nathalie Murphy, et al.
World Journal of Advanced Research and Reviews (2024) Vol. 21, Iss. 3, pp. 885-915
Open Access | Times Cited: 1
Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
Justin Faden, Ryan Serdenes, Leslie Citrome
Expert Review of Neurotherapeutics (2022) Vol. 22, Iss. 5, pp. 365-376
Closed Access | Times Cited: 7
A Novel Bioanalytical Method for Simultaneous Determination of Olanzapine and Samidorphan in Human Plasma Using RP-HPLC
Bonagiri Pavani, M. Narender, DSNBK Prasanth, et al.
Indian Journal of Pharmaceutical Education and Research (2023) Vol. 57, Iss. 3, pp. 873-882
Open Access | Times Cited: 3
Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence
Xinyi Li, Daniel D. Langleben, Kevin G. Lynch, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 3
Olanzapine-Samidorphan for Schizophrenia: A Systematic Review and Meta-Analysis
Dhyuti Gupta, Alok Singh
Indian Journal of Psychological Medicine (2023) Vol. 46, Iss. 1, pp. 14-23
Open Access | Times Cited: 2
In vivo Characterization of the Opioid Receptor–Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations
Laura A. Tan, Nileshkumar Gajipara, Lei Sun, et al.
Neuropsychiatric Disease and Treatment (2022) Vol. Volume 18, pp. 2497-2506
Open Access | Times Cited: 4
Opioid antagonists: clinical utility, pharmacology, safety, and tolerability
Roger S. McIntyre, M. L. HARRIS, Mark S. Todtenkopf, et al.
CNS Spectrums (2024), pp. 1-7
Open Access
Is samidorphan adjunction a beacon of hope for olanzapine-induced metabolic syndrome?
Yasin Hasan Balcıoğlu
Dusunen Adam The Journal of Psychiatry and Neurological Sciences (2022)
Open Access
Page 1

Scroll to top